Compare Interactive Brokers Group Inc. Class A Common Stock (IBKR) vs Revolution Medicines Inc. Common Stock (RVMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Interactive Brokers Group Inc. Class A Common Stock vs Revolution Medicines Inc. Common Stock — how do they compare? Interactive Brokers Group Inc. Class A Common Stock trades at $88.22 (market cap $39.18B), while Revolution Medicines Inc. Common Stock trades at $189.32 (market cap $40.32B). The key difference: Interactive Brokers Group Inc. Class A Common Stock and Revolution Medicines Inc. Common Stock are close in size by market cap, and Interactive Brokers Group Inc. Class A Common Stock pays a 0.4% dividend while Revolution Medicines Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Interactive Brokers Group Inc. Class A Common Stock for 1 Days and Revolution Medicines Inc. Common Stock for 0 Days on average.
| IBKR | RVMD | |
|---|---|---|
Market Cap | $39.18B | $40.32B |
Volume | 2,996,599 | 4,855,734 |
Sector | Financials | Health |
52-Week High | $98.19 | $221.15 |
52-Week Low | $61.05 | $47.50 |
Typical Hold Time | 1 Days | 0 Days |
Enterprise Value | $31.48B | $37.02B |
Dividend Yield | 0.4% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Interactive Brokers Group Inc. Class A Common Stock
Interactive Brokers operates an electronic brokerage platform for trading stocks, options, futures, currencies, and other assets. It also provides clearing and custody services.
Read more on IBKR →About Revolution Medicines Inc. Common Stock
Revolution Medicines develops precision medicines for cancer. Its programs focus on targeting RAS-driven cancers and related signaling pathways.
Read more on RVMD →
